Gamma Knife Offers New Hope For Trigeminal Neuralgia Patients
There is now new hope on the horizon for trigeminal
neuralgia patients as researchers have found that Gamma Knife Stereotactic Radiosurgery (GKRS) is an effective way to deal with the pain caused by the condition.//
Researchers at the Comprehensive Cancer Center at Wake Forest University Bapt...
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
...on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by it...
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer
...2 percent), constipation (31 percent vs 31 percent), mucositis/stomatitis (20 percent vs 5 percent), peripheral neuropathy (42 percent vs 45 percent),
neuralgia (17 percent vs 20 percent), and rash (22 percent vs 18 percent)
In addition, 19 percent vs less than 1 percent reported HFS
...
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
...on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by it...
Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications
...."
CyberKnife radiosurgery offers a non-surgical treatment option for benign and cancerous tumors, as well as other conditions such as trigeminal
neuralgia and AVMs.
Accuray is exhibiting at booth #1126. Please visit http://www.aans.org/Annual for more information on this year's meeting.
...
New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans
...ounced the re-launch of AfterShingles.com, an online resource offering tools and information to help educate consumers about shingles and postherpetic
neuralgia (PHN), or after-shingles pain, its impact on people's lives and steps to take to help manage the conditions.
"AfterShingles.com is a consumer-fo...
NeurogesX Reports Fourth Quarter and Year-End 2008 Results
...approval of Qutenza for the management of pain associated with postherpetic
neuralgia (PHN). In December 2008, the NDA was accepted by the FDA for review, result...ial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diab...
Chronic Pain Patients Now Have Hope With Carryover Pain Relief Provided By Repeated Interferential Treatments
... Pain
· Restless Leg Syndrome ( RLS)
· Cervical Spondylosis
· Trigeminal
neuralgia
· Reflex Sympathetic Dystrophy ( RSD)
· Carpal Tunnel Syndrome ( CTS)
The new interferential/...
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
...utropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy
(47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37%
vs 16%),
neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs
16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%),
anorexia (23% vs 10...
NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
...ey milestones. In September, we
announced positive results from our second Phase 3 trial of our dermal
patch drug candidate, NGX-4010, in postherpetic
neuralgia (PHN). We expect
to file a new drug application (NDA) with the U.S. Food and Drug
Administration (FDA) later this year in PHN. Additionally, we are
co...
Neuralgia in Medical Technology
NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
SAN MATEO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the publication of Phase 3 data of its lead product candidate, Qutenza (NGX-4010), for ...
Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Epiphany Biosciences, Inc. today
announced that a Phase 2b dose-ranging study to evaluate the safety,
efficacy, and tolerability of the company's lead compound, valomaciclovir
(EPB-348) in patients with acute herpes zoster infection (shingles), will
conti...
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
Potential Seven Years Market Exclusivity in PHN Pending Product Approval
SAN MATEO, Calif., June 2 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the Offic...
Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Solace Pharmaceuticals, a
private biotechnology company discovering and developing innovative treatments
for pain, announced the initiation of a proof-of-concept clinical trial of
SLC022 in patients with post-herpetic
neuralgia (PHN). PHN, a painful
co...
ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
CUPERTINO, Calif., June 30 /PRNewswire-FirstCall/ -- DURECT Corporation
(Nasdaq: DRRX ) announced today that the US Food and Drug Administration
(FDA) has granted to DURECT orphan drug designation for bupivacaine for
relief of persistent pain associated with post-herpetic
neuralgia (PHN).
Bup...
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Trial Meets Primary and All Secondary Endpoints
San Carlos, Calif., Sept. 4 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX ), a biopharmaceutical company focused on developing novel
pain management therapies, today announced positive top-line results from
its second pivot...
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
...rm clinical study (Study C123) of Qutenza(TM) in patients with postherpetic
neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As pa...ial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diab...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
...ea (46% vs 39%), vomiting (32% vs 22%),
constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral
neuropathy (42% vs 45%),
neuralgia (17% vs 20%), and rash (22% vs 18%)
- In addition, 19% vs <1% reported HFS
* In patients with AIDS related Kaposi's sarcoma, ARs repo...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
...utropenia (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% vs 55%), constipation (37% vs 16%),
neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
...utropenia (49% vs 46%),
nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%),
anemia (43% vs 55%), constipation (37% vs 16%),
neuralgia (36% vs 1%),
leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue
(29% vs 26%), lymphopenia (24% vs 17%), anorexia (23% vs 10...
Neuralgia in Medical Dictionary
Neuralgia
Neuralgia or neuropathic pain can be defined most simply as non-nociceptive pain, or in other words, pain that is not related to activation of pain receptor cells in any part of the body.
Neuralgia is pain produced by a change in neurological structure or function.... Trigeminal ne...
Trigeminal neuralgia
... trigeminal
neuralgia ... Trigeminal
neuralgia (TN) or tic douloureux (also known as ... suggest that ATN may be an early development of Trigeminal
Neuralgia . ... Trigeminal
neuralgia (TN) or tic douloureux is a neuropathic disorder of one or both of the faci...
Zoster
...... Features illustrated information on the disease and postherpetic
neuralgia including symptoms, ... virus is called the Varicella zoster virus (... Herpes zoster (commonly referred to as "shingles") and postherpetic
neuralgia ... Reactivation of latent varicella- zoster virus from dorsal root g...
Tic douloureux
... Trigeminal
neuralgia (TN) or tic douloureux is a neuropathic disorde... Douloureux ... The typical symptom of Trigeminal
neuralgia is excruciatingly ... It usually begins at the mou...ux , is a painful disorder of a ... Trigeminal
neuralgia ( tic doloreaux) information compiled by NINDS, t...
Shingles
... often in a stripe. The initial infection with varicella zoster virus... Features illustrated information on the disease and postherpetic
neuralgia including symptoms, causes, complications, and treatment. Watch this slideshow of shingles (herpes zoster virus) pictures and learn about cau...
Herpes zoster
...oster ophthalmicus can also lead to weakness or partial paralysis ... Features illustrated information on the disease and postherpetic
neuralgia including symptoms, ... Varicella zoster virus (VZV) and is in the Herpes family ... Herpes zoster , commonly known as shingles, is caus...
Face pain
...ly (is it recurrent)? How long have the episodes ... Did face pain occur prior to developing a brain or nervous system problem ... Trigeminal
neuralgia is classically triggered pain . So if you touch the face , it will trigger it. ... Copyright, 2008, Face the Pain . Question. of the Month: ... ...
Neuralgia in Biological News
Clinical trials for shingles drug take an important step forward
...g condition during their lifetime. It is generally characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic
neuralgia (PHN), which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Inhibitex believes FV-100 has the po...
Experimental shingles vaccine proves effective in nationwide study
...ipients. Moreover, the zoster vaccine reduced the incidence of postherpetic
neuralgia (PHN)--a form of chronic nerve pain that is the most common serious complic... the side of the body that is affected can be excruciating.
Postherpetic
neuralgia is difficult to treat. Antiviral medications can speed the healing of shing...
Neuralgia in Biological Technology
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
Marketing Application Submitted on Schedule
SAN MATEO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX ), a biopharmaceutical company focused on developing and
commercializing novel pain management therapies, announced today that it
has submitted a new drug applicati...
NeurogesX Reports Second Quarter 2009 Results
...f the ongoing new drug application (NDA) review for Qutenza in postherpetic
neuralgia (PHN). These requests included a short-term Qutenza study (Study C123) to d...ial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diab...
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
...plication (NDA) for Qutenza(TM) to manage pain associated with postherpetic
neuralgia (PHN).
The extension resulted from the Company's recent submission ...ial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diab...
NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
...on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by it...
Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
...n the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic
neuralgia (PHN). Solace's research and development are supported by a strong and expanding intellectual property portfolio. For more information, please visit ...
NeurogesX Added to Russell 3000 Index
...on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by it...
NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
...o its proposed study to evaluate Qutenza(TM) in patients with post-herpetic
neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As pa...ial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diab...
NeurogesX to Present at Needham Life Sciences Conference
...on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by it...
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
...s 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral neuropathy (42% vs 45%),
neuralgia (17% vs 20%), and rash (22% vs 18%)
In addition, 19% vs <1% reported HFS
In patients with AIDS related Kapo...
NeurogesX Receives European Commission Approval for Qutenza(TM)
...he management of pain associated with postherpetic
neuralgia (PHN). In December 2008, the NDA was accepted by t... can result from viruses, in cases of postherpetic
neuralgia (PHN) and painful HIV-distal sensory polyneuropath...eripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (...
Neuralgia in Biological Definition
Varicella zoster virus
...out 10-20% of cases, VZV later reactivates later in life to produce herpes zoster (shingles) and its associated sequelae including: post-herpetic
neuralgia , zoster multiplex, myelitis, herpes ophthalmicus, or zoster sine herpete.
VZV is closely related to the herpes simplex viruses (HSV), sharing muc...
Neuralgia in Biological Dictionary
Olfactory nerve
...nonyms, Olfactory nerves antonyms. Information about Olfactory nerves ... nerve (redirected from Olfactory nerves ) ... End Trigeminal
neuralgia With Our Ground-Breaking ... Nerve Pain. Brain Age. The Brain Garden. Do Muscle Cells Grow. Sciatica Nerve . Bleeding Brain Stroke ... Today in ...